nach oben

Erschienen in:

06.03.2017 | Original Article

FLAIRfusion Processing with Contrast Inversion

Improving Detection and Reading Time of New Cerebral MS Lesions

verfasst von: M. A. Schmidt, R. A. Linker, S. Lang, H. Lücking, T. Engelhorn, S. Kloska, M. Uder, A. Cavallaro, A. Dörfler, P. Dankerl

Erschienen in: Clinical Neuroradiology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the performance of an innovative image processing approach for detection of T2-weighted hyperintense multiple sclerosis (MS) lesions.

Methods

In this study 20 consecutive patients with inflammatory demyelinating lesions were retrospectively evaluated of whom 10 patients featured progressive disease and 10 a stable lesion load. 3 mm transversal FLAIRfusion imaging was processed and archived. Image processing was performed through landmark-based 3D co-registration of the previous and current isotropic FLAIR examination followed by inversion of image contrast. Thereby, the hyperintense signals of the unchanged MS plaques extinguish each other, while newly developed lesions appear bright on FLAIRfusion. Diagnostic performance was evaluated by 4 experienced readers. Consensus reading supplied the reference standard. Sensitivity, specificity, NPV (negative predictive value), PPV (positive predictive value), interreader agreement and reading time were the outcome measures analyzed.

Results

Combined sensitivity was 100% at a specificity of 88.2%, with PPV ranging from 83.3% to 90.1% and NPV at 100%. Reading time was nearly 5‑fold faster than conventional side by side comparison (35.6 s vs. 163.7 s, p < 0.001). Cohen’s kappa was excellent (>0.75; p < 0.001) and Cronbach’s alpha was 0.994.

Conclusion

FLAIRfusion provides reliable detection of newly developed MS lesions along with strong interreader agreement across all levels of expertise in 35 s of reading time.

Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.CrossRefPubMed

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for Multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.CrossRefPubMedPubMedCentral

Comi G. Disease-modifying treatments for progressive multiple sclerosis. Mult Scler J. 2013;19:1428–36.CrossRef

Río J1, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting Multiple sclerosis patients. Mult Scler J. 2008;14:479–84.CrossRef

Prosperini L, Mancinelli CR, De Giglio L, De Angelis F, Barletta V, Pozzilli C. Interferon beta failure predicted by EMA criteria or isolated MRI activity in Multiple sclerosis. Mult Scler J. 2014;20:566–76.CrossRef

Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in Multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12:669–76.CrossRefPubMed

Abraham AG, Duncan DD, Gange SJ, West S. Computer-aided assessment of diagnostic images for epidemiological research. BMC Med Res Methodol. 2009;9:74.CrossRefPubMedPubMedCentral

Dankerl P, Cavallaro A, Dietzel M, Tsymbal A, Kramer M, Seifert S, Uder M, Hammon M. Clinical evaluation of semi-automatic landmark-based lesion tracking software for CT-scans. Cancer Imaging. 2014;14:6.PubMedPubMedCentral

Garcia-Lorenzo D, Francis S, Narayanan S, Arnold DL, Collins DL. Review of automatic segmentation methods of Multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Med Image Anal. 2013;17:1–18.CrossRefPubMed

10.

Cabezas M, Oliver A, Roura E, Tsymbal A, Kramer M, Seifert S, Uder M, Hammon M. Automatic Multiple sclerosis lesion detection in brain MRI by FLAIR thresholding. Comput Methods Programs Biomed. 2014;115:147–61.CrossRefPubMed

11.

Schmidt P, Gaser C, Arsic M, Buck D, Förschler A, Berthele A, Hoshi M, Ilg R, Schmid VJ, Zimmer C, Hemmer B, Mühlau M. An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple sclerosis. Neuroimage. 2012;59:3774–83.CrossRefPubMed

12.

van Heerden J, Rawlinson D, Zhang AM, Chakravorty R, Tacey MA, Desmond PM, Gaillard F. Improving Multiple sclerosis plaque detection using a semiautomated assistive approach. AJNR Am J Neuroradiol. 2015;36:1465–71.CrossRefPubMed

13.

Moraal B, Meier DS, Poppe PA, Geurts JJ, Vrenken H, Jonker WM, Knol DL, van Schijndel RA, Pouwels PJ, Pohl C, Bauer L, Sandbrink R, Guttmann CR, Barkhof F. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology. 2009;250:506–14.CrossRefPubMed

14.

N’gbo N’gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP. Immune-reconstitution inflammatory syndrome in Multiple sclerosis patients treated with natalizumab: a series of 4 cases. Clin Ther. 2016;38:670–5.CrossRefPubMed

15.

Hodel J, Outteryck O, Dubron C, Dutouquet B, Benadjaoud MA, Duhin E, Verclytte S, Zins M, Luciani A, Rahmouni A, Pruvo JP, Vermersch P, Leclerc X. Asymptomatic progressive Multifocal Leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging. Radiology. 2016;278:863–72.CrossRefPubMed

16.

Dubey D, Cano CA, Stüve O. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of Multiple sclerosis. Curr Opin Neurol. 2016;29(3):278-85.CrossRefPubMed

17.

Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72:779–87.CrossRefPubMed

18.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D. Lessons learned from fatal progressive Multifocal Leukoencephalopathy in a patient with Multiple sclerosis treated with natalizumab. JAMA Neurol. 2013;70:398–402.CrossRefPubMed

19.

Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D. Revised recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol. 2016;37:394–401.CrossRefPubMed

20.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive Multifocal Leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–46.CrossRefPubMed

21.

Honce JM, Nagae L, Nyberg E. Neuroimaging of natalizumab complications in Multiple sclerosis: PML and other associated entities. Mult Scler Int. 2015;2015:809252.PubMedPubMedCentral

22.

Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016;29:365–76.CrossRefPubMedPubMedCentral

23.

Runge VM. Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus. Invest Radiol. 2016;51:273–9.PubMed

Titel: FLAIRfusion Processing with Contrast Inversion
Improving Detection and Reading Time of New Cerebral MS Lesions
verfasst von: M. A. Schmidt
R. A. Linker
S. Lang
H. Lücking
T. Engelhorn
S. Kloska
M. Uder
A. Cavallaro
A. Dörfler
P. Dankerl
Publikationsdatum: 06.03.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Neuroradiology / Ausgabe 3/2018
Print ISSN: 1869-1439
Elektronische ISSN: 1869-1447
DOI: https://doi.org/10.1007/s00062-017-0567-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

FLAIRfusion Processing with Contrast Inversion

Improving Detection and Reading Time of New Cerebral MS Lesions